24 October 2013
PHOSPHAGENICS' OXYMORPHONE PATCH SUCCESS
- Oxymorphone patch achieves world first therapeutic plasma concentrations in all subjects in clinical trial
- Results from Phase 1 oxymorphone patch clinical trial demonstrates excellent drug delivery profile
- Most commercially significant trial result ever achieved by Phosphagenics as it proves the concept for an estimated $1 billion annual sales
- Phase 2 study to proceed focusing on optimising commercial appeal of the patch
Phosphagenics today announced results from its multi-dose oxymorphone Phase 1 trial. In a world first, the Company's proprietary TPM/oxymorphone patch delivered therapeutic plasma concentrations of oxymorphone to all 12 subjects.